Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor, is Efficacious in Mouse Models of Lupus Nephritis and Reduces Human Lymphocyte Lifespan in vitro

被引：0
|
作者：
Wang, L. [1 ]
Perper, S. [1 ]
Grebe, K. [1 ]
Schwartz, A. [1 ]
Goess, C. [1 ]
O'Connor, L. [1 ]
Hartman, D. [1 ]
Westmoreland, S. [1 ]
Graff, C. [1 ]
Souers, A. [2 ]
Leverson, J. [2 ]
Elmore, S. [2 ]
Olson, L. [1 ]
机构：
[1] Abbvie Inc, Worcester, MA USA
[2] Abbvie Inc, N Chicago, IL USA
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P4.24
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [31] Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
    Phillips, D. C.
    Xiao, Y.
    Lam, L. T.
    Litvinovich, E.
    Roberts-Rapp, L.
    Souers, A. J.
    Leverson, J. D.
    BLOOD CANCER JOURNAL, 2015, 5 : e368 - e368
  • [32] Synergistic Growth Inhibition of NPM1 Mutant AML PDX By Combined Therapy with BCL-2 Inhibitor Venetoclax ( ABT-199) and Menin Inhibitor DS-1594b In Vivo
    Ciaurro, Valerio
    Konopleva, Marina Y.
    Daver, Naval
    Skwarska, Anna
    Martelli, Maria Paola
    BLOOD, 2023, 142
  • [33] The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199
    Nii, Takenobu
    Ishizawa, Jo
    Prabhu, Varun Vijay
    Ruvolo, Vivian
    Madhukar, Neel
    Zhao, Ran
    Mu, Hong
    Heese, Lauren
    Kojima, Kensuke
    Garnett, Mathew
    McDermott, Ultan
    Benes, Cyril H.
    Charter, Neil
    Deacon, Sean
    Elemento, Olivier
    Allen, Joshua E.
    Oster, Wolfgang
    Stogniew, Martin
    Andreeff, Michael
    BLOOD, 2017, 130
  • [34] Erratum: Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
    D C Phillips
    Y Xiao
    L T Lam
    E Litvinovich
    L Roberts-Rapp
    A J Souers
    J D Leverson
    Blood Cancer Journal, 2016, 6 : e403 - e403
  • [35] BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment
    Padua, Rose Ann
    Sarda-Mantel, Laure
    Chiquet, Mathieu
    Kappel, Claire
    Krief, Patricia
    Setterblad, Niclas
    Hontonnou, Fortune
    Hosten, Benoit
    Vignal, Nicolas
    Zassadowski, Fabien
    Cassinat, Bruno
    Gou, Panhong
    Giraudier, Stephane
    Konopleva, Marina Y.
    Andreeff, Michael
    Marika, P. L. A.
    Ades, Lionel
    Fenaux, Pierre
    Chomienne, Christine
    BLOOD, 2018, 132
  • [36] Inhibition of XPO1 By KPT-330 (Selinexor) Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor ABT-199 (Venetoclax) through Downregulation of Mcl-1 in Acute Myeloid Leukemia
    Luedtke, Daniel A.
    Su, Yongwei
    Edwards, Holly
    Lin, Hai
    Taub, Jeffrey W.
    Ge, Yubin
    BLOOD, 2017, 130
  • [37] Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus
    Nader, Ahmed
    Minocha, Mukul
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2020, 59 (03) : 335 - 347
  • [38] Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus
    Ahmed Nader
    Mukul Minocha
    Ahmed A. Othman
    Clinical Pharmacokinetics, 2020, 59 : 335 - 347
  • [39] Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
    Wang, Beatrice T.
    Kothambawala, Tasnim
    Wang, Ling
    Matthew, Thomas J.
    Calhoun, Susan E.
    Saini, Avneesh K.
    Kotturi, Maya F.
    Hernandez, Genevive
    Humke, Eric W.
    Peterson, Marvin S.
    Sinclair, Angus M.
    Keyt, Bruce A.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12) : 2483 - 2494
  • [40] MCL-1 Up-Regulation through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML Models
    Zhang, Qi
    Han, Lina
    Pan, Rongqing
    Shi, Ce
    Jeremy, Ryan
    Ma, Man Chun John
    Kurtz, Steven
    Mu, Hong
    Ruvolo, Vivian R.
    Ma, Helen
    Mi, Yingchang
    Tyner, Jeffrey
    Anthony, Letai
    Davis, Richard Eric
    Andreeff, Michael
    Konopleva, Marina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S2 - S2
12345